drugset / Trial / NCT04159818
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single center non-blinded randomized multi-cohort non-comparative phase II trial with a Simon's two-stage design.
Timeline
- Start
- 2020-02-21
- Primary completion
- 2022-12-15
- Completion
- 2026-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 15 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |